Factors associated with discontinuation of bupropion and counseling among african american light smokers in a randomized clinical trial

Nicole L. Nollen, Matthew S. Mayo, Jasjit S. Ahluwalia, Rachel F. Tyndale, Neal L. Benowitz, Babalola Faseru, Taneisha S. Buchanan, Lisa Sanderson Cox

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Background: African Americans are at risk of inadequate adherence to smoking cessation treatment, yet little is known about what leads to treatment discontinuation. Purpose: The purpose of this study was to examine the factors associated with discontinuation of treatment in African American light smokers (≤10 cigarettes per day). Methods: Bupropion plasma levels and counseling attendance were measured among 540 African American light smokers in a placebo-controlled randomized trial of bupropion. Results: By week 3, 28.0 % of subjects in the bupropion arm had discontinued bupropion, and only moderate associations were found between the plasma levels and self-reported bupropion use (r s = 0.38). By week 16, 36.9 % of all subjects had discontinued counseling. Males had greater odds of discontinuing medication (OR = 2.02, 95% CI = 1.10-3.71, p = 0.02), and older adults had lower odds of discontinuing counseling (OR = 0.96, 95% CI = 0.94-0.97, p < 0.0001). Conclusions: Bupropion and smoking cessation counseling are underutilized even when provided within the context of a randomized trial. Future research is needed to examine strategies for improving treatment utilization among African American smokers. Trial Registration No. NCT00666978 (www.clinicaltrials.gov).

Original languageEnglish (US)
Pages (from-to)336-348
Number of pages13
JournalAnnals of Behavioral Medicine
Volume46
Issue number3
DOIs
StatePublished - Dec 2013

Keywords

  • African Americans
  • Discontinuation of treatment
  • Smoking cessation

Fingerprint Dive into the research topics of 'Factors associated with discontinuation of bupropion and counseling among african american light smokers in a randomized clinical trial'. Together they form a unique fingerprint.

Cite this